Navigation Links
Light activated anticancer drug targeted to DNA using cisplatin like sub-units

One of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. However, it also kills healthy tissue. Many scientists are creating alternative drugs or cisplatin analogs in attempts to find treatments without side effects. One approach to analog development is light activated drugs, or photodynamic therapy (PDT). Now a Virginia Tech chemistry-biology research team that has been working on both non-cisplatin drugs and cisplatin analogs has combined their findings to create a molecular complex (supramolecule) that exploits cisplatins tumor targeting to deliver a light activated drug.

The latest results from the group's research to create a DNA targeting, light activated anticancer drug will be presented at the 231st American Chemical Society national meeting in Atlanta on March 26-30.

Chemistry professor Karen J. Brewer reports that the group has developed supramolecular complexes that combine light-absorbing PDT agents and cisplatin like units. Previous anticancer molecules created by the group have contained platinum-based molecules that bind DNA. They have also developed new light activated systems able to photocleave DNA. This report combines these two approaches to target the drug to DNA using cisplatin like units, directing the light activation to tumor cells and the sub-cellular target, DNA.

"In the past, our light activated systems had to find the DNA within the cell, an often inefficient process. Now we have added the DNA targeting drug," Brewer said. "We were working on cisplatin analogs before, so we have tied it to light activated systems."

Cisplatin begins its interaction with cancer DNA by binding to the nitrogen atoms of the DNA bases, typically guanine. Our new supramolecules use this nitrogen-binding site to hold the light activated drug at the target until signaled to activate. Thus the new supramolecules can be delivered to the tumor site but remain ine rt until activated by a light signal. Light waves in the therapeutic range ?that is, those that can penetrate tissue, are used to activate these new drugs. t The researchers are also appending other molecules that emit UV light to track the movement of these drugs within cells.

Virginia Tech chemistry graduate student Ran Miao will discuss how component identity dictates device properties. He will present the paper, "Synthesis and properties of mixed-metal Ru-Pt complexes: Coupling light absorbers to reactive metal centers" (INOR 105) at 3:30 p.m., Sunday, March 26, at the Georgia World Congress Center room B408. Co-authors are Matthew T. Mongelli, postdoctoral associate in chemistry at Virginia Tech, and Brewer.


Source:Virginia Tech

Related biology news :

1. Light therapy may combat fungal infections, new evidence suggests
2. New Research Shows Artificial Light at Night Stimulates Breast Cancer Growth in Laboratory Mice
3. Light guides flight of migratory birds
4. Light-sensitive photoswitches could restore sight to those with macular degeneration
5. Light wine intake is associated with longer life expectancy in men
6. Light-based probe sees early cancers in first tests on human tissue
7. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
8. T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
9. Reactivated gene shrinks tumors
10. New drug shows promise as powerful anticancer agent
11. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
Post Your Comments:

(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Inc., on being named to Deloitte's 2015 Technology Fast 500 list of the ... manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic tooth ...
(Date:11/24/2015)... 2015 Capricor Therapeutics, Inc. (NASDAQ: ... discovery, development and commercialization of first-in-class therapeutics, today announced ... is scheduled to present at the 2015 Piper Jaffray ... EST, at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology: